Local News: Pomerene, AZ 

 | 

Sign Up

 | 

Sign In

Advertisment

Schering Plough News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Schering Plough News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Schering Plough News

News on Schering Plough continually updated from thousands of sources around the net.

Sunday | Industrial Maintenance & Plant Operat...

Merck Eager For More Takeovers

The new Merck & Co. becomes the world's second-biggest drugmaker overnight, and it's boasting a fat wallet to fund future deals.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry

Sat Nov 07, 2009

The Motley Fool

A Little Distracted, Are You, Merck?

What's the only thing more embarrassing for a drugmaker than getting a "complete response letter" for a New Drug Application from the Food and Drug Administration? Having the FDA refuse to file its NDA in the first place.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Food and Drug Administration, Pfizer

Fri Nov 06, 2009

KXMB-TV Bismarck

Merck, now No. 2 drugmaker, set for future buys

KXNet.com North Dakota News _title> _head> _script> _script> JavaScript DHTML Dro0 Down Men5 By Milonic _a> _div> Merck, now No.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry

Thu Nov 05, 2009

Drugs.com

Data Supporting Boceprevir Response Guided Therapy Presented at...

Schering-Plough Corporation today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases Annual Meeting in Boston, Oct.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health

MediLexicon

Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary ...

Schering-Plough Corporation announced that its investigational sublingual Grass Allergy Immunotherapy Tablet has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Allergy, Health

The Daily News

Merck, Now No. 2 Drugmaker, Set for Future Buys

The new Merck & Co . has become the world's second-biggest drugmaker overnight with a huge acquisition, but it still has a fat wallet and plans more wheeling and dealing.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Pfizer, Whitehouse Station, NJ, Kenilworth, NJ, Opinion

Wed Nov 04, 2009

The Motley Fool

An Ode to Schering-Plough

Technically, Schering lives on as a quirk; It was a reverse merger , after all. But after Schering bought Merck As "Merck," it answers the call.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Johnson and Johnson, Bristol Myers Squibb, Eli Lilly, SanofiSynthlabo

Bioscience Technology

1310States:NJ,NY,BA; US:DSF; Intl:; Fmts:Print, Online, Broadcast;...

Merck disclosed the rare move by the Food and Drug Administration in a regulatory filing Monday.

Comment?

Related Topix: Medicine, Cholesterol, Health, Lipitor, Atorvastatin (generic), Medication, Food and Drug Administration, Biotech, Healthcare Industry, Zetia, Ezetimibe (generic), Whitehouse Station, NJ

GuruFocus.com

Enzon Inc. Reports Operating Results

Enzon Inc. filed Quarterly Report for the period ended 2009-09-30. Enzon Pharmaceuticals Inc.

Comment?

Related Topix: Biotech, Medicine, Enzon Pharmaceuticals, Healthcare Industry, Sales, Marketing

Tue Nov 03, 2009

BioSpace

FDA Concerns Remain Over New Use for Schering-Plough Corporation Drug, PegIntron

Schering-Plough Corp. announced today the U.S. Food and Drug Administration has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRONA for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Food and Drug Administration, Law

Drug Store News

FDA rejects expanded use of Pegintron

KENILWORTH,A N.J. The Food and Drug Administration has rejected an approval application for an additional use for a hepatitis C drug.

Comment?

Related Topix: Food and Drug Administration, Biotech, Medicine, Healthcare Industry, Hepatitis, Health

Drugs.com

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir...

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir , an Investigational, Once-Daily Protease Inhibitor for Hepatitis C Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases Annual Meeting BOSTON, Nov.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis

Mon Nov 02, 2009

Freshnews

Schering-Plough Announces Sponsorship of Rabies-Control Projects in India

Schering-Plough Corporation today announced it has initiated sponsorship of two projects in India to reduce the incidence of human and animal rabies through improved educational awareness and mass vaccination of dogs.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, World News, India,

The New Braunfels Herald

FDA won't accept Merck's application for new drug

U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

Comment?

Related Topix: Biotech, Merck , Medicine, Healthcare Industry, Food and Drug Administration, Cholesterol, Health, Lipitor, Atorvastatin (generic), Medication, Zetia, Ezetimibe (generic)

The News Tribune

Schering-Plough reports data on hepatitis C drug

Schering-Plough Corp. said its experimental hepatitis C drug boceprevir helped eliminate the virus in about half of patients who did not respond to standard treatments.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Kenilworth, NJ

Sun Nov 01, 2009

TheStreet.com

Vertex Hep C Drug Cures 80% at New Dose: Study

More than 80% of hepatitis C patients were cured after treatment with a new twice-daily dose of the experimental drug telaprevir made by Vertex Pharmaceuticals , according to data from a phase II study released Saturday.

Comment?

Related Topix: Biotech, Vertex Pharmaceuticals, Medicine, Healthcare Industry, Hepatitis, Health, Business News

Sat Oct 31, 2009

Medical News

Schering-Plough receives FDA complete response letter regarding PEGINTRON for malignant melanoma

Schering-Plough Corp. announced today the U.S. Food and Drug Administration has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRONA for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Food and Drug Administration, Law, Health

Fri Oct 30, 2009

Federal Trade Commission

FTC Order Restores Competition Lost Through Schering-Plougha s Acquisition of Merck

Merck & Co., Inc. must sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and Schering-Plough must sell its assets related to significant drugs for nausea and vomiting in humans, in order for Schering-Plough to complete its proposed $41.1 billion acquisition of Merck, the Federal Trade Commission announced ...

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck , SanofiSynthlabo

Thu Oct 29, 2009

CBS News

Merck's Buy Of Schering-Plough Gets FTC Approval

Merck & Co. and Schering-Plough Corp. said Thursday they have won merger approval from the Federal Trade Commission and antitrust regulators in Switzerland and Canada.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Merck

Chicago Tribune

Freeport-McMoRan to replace Schering-Plough after merger with Merck, Priceline joins S&P 500

Standard & Poor's said Thursday it will add miner Freeport-McMoRan Copper & Gold Inc.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Real Estate, Merck , Mining, FreeportMcMoRan Copper and Gold, Business News

Pomerene Jobs

Also on Topix